Participation in CPhI Worldwide – the engine for multiplying the export of Antibiotice
Multiplying more than 7 times the export
Market shares of over 30-40% in the US, UK and Vietnam
Between November 1-3, 2022, Antibiotice Iași is present in Frankfurt, at the most important exhibition event of the world pharmaceutical industry, CPhI Worldwide. The company has had a continuous presence at this fair for nearly 20 years, and this has led to a more than 7-fold increase in exports.
“We are here, at this international event, to convey a message of stability and continuity to our partners. It is necessary to always be in contact with traditional partners but also to make ourselves known to potential partners, in order to support our long-term business goals. We set out to export more than 50% of our turnover by 2025, and by 2030 to finance 3-4 extremely important investments in new manufacturing sites and a modern research center. Thus, we are already enabling partners from all over the world to maintain open contacts for these investments”, said Ioan NANI, general director of Antibiotice.
The Antibiotice delegation at CPhI Worldwide, made up of specialists in the fields of research and development, import, export, business development, will have meetings with business partners from all over the world, in an effort to capitalize on the research capabilities and production infrastructure on the modern manufacturing platform from Iasi. Thus, future sales strategies will be established, as well as possibilities for the development of new pharmaceutical products. Following these business meetings, the company has always identified new business and expansion opportunities on the global market.
Looking ahead, Antibiotice aims to accelerate development on the international market, and in this context, the constant participation in the CPhI Worldwide exhibition has proven to be a real engine for the growth of Antibiotice exports. This fact made the Romanian Antibiotice brand increasingly present on the international pharmaceutical markets.
Thus, in Great Britain, Antibiotice succeeded by winning the regional tenders organized by the NHS (National Health Service) authority to hold a market share of approx. 30% calculated at the level of annual national consumption for an anti-infective drug with injectable administration – Amoxiplus® (amoxicillin/clavulanic acid).
In the United States, Antibiotice has become one of the leading suppliers of sterile injectable anti-infectives. The business has consolidated over time, by increasing the number of products
registered in this country and by an extended territorial coverage ensured by the collaboration with big 4 partner-distributors. This provides sustainability to the Antibiotics business and reconfirms its status as a drug supplier in the world’s largest regulated market.
For Nafcillin, also an injectable anti-infective drug, Antibiotice has a 27% market share in the US market (according to IQVIA market data).
In Vietnam, a market accessed 10 years ago by Antibiotice, for the Ampiplus® and Amoxiplus® product ranges, the company has a market share of 42% and 33% respectively of the national consumption.
In addition to the export of injectable anti-infective drugs, Antibiotice aims to become an established international manufacturer of topical (dermatological) and sterile products (sterile injectable solutions and powders) and also to maintain its status as a world leader in the production of the active substance Nystatin.
Antibiotice Iași is the most important Romanian manufacturer of medicines, with international recognition, which exports to over 70 countries around the world.
